Corporate Presentation 0 Disclaimer Certain statements in this - PowerPoint PPT Presentation

Corporate Presentation 0

Disclaimer Certain statements in this document are forward looking based on management's current expectations but actual events may differ materially due to various factors. These statements are related but not limited to future objectives, plans, status, events, circumstances, progress and outcome of research and development, potential product attributes, usage, launch dates and sales potential, changes in the value of rupee and other foreign currencies and environmental changes. These forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. 1 1

Jubilant Bhartia Group - S napshot Pharmaceuticals & Agri & Polymers Food Oil & Gas Services Auto Life Sciences And Retail A master franchise of Aerospace Integrated Outsourcing Leading player in Agri Engaged in the upstream oil Exclusive dealership of Domino’s Pizza for India, Audi make cars in Solutions Provider for Products in North India, and gas exploration and Sole authorized Independent Bangladesh, Nepal & Sri Karnataka and Pharmaceutical & Life Sciences Caters to niche markets in production sector Representative of Bell Industry Performance Polymers Lanka and Dunkin’ Donuts Helicopter in India for sales, Tamil Nadu marketing and customer globally for India; Domino’s has Portfolio of 9 blocks in support. presence in 118 cities Service center for Audi India through over 552 stores in Also represent other cars in Bengaluru India’s largest CRAM s Company 2 nd largest retailer in India international aerospace and Chennai Producing Asset – Kharsang Bengaluru operating 5 companies. 8 Dunkin’ Donuts stores hypermarket-cum-malls Development Asset – Custom Paint and Body opened since M ay 2012, in Oil & Gas Services KG block workshop in Bengaluru Delhi NCR • Consultant to Transocean- Revenues FY2012: Revenue FY 2012: offshore drilling company Revenues FY 2012: Revenues FY 2012: US $ 892 M n (Rs.4,278 Crs) US $ 207 M n (Rs. 996 Crs) • M anning and M arketing US$ 212 M n (Rs. 1,018 Crs) US$ 19.06 M n (Rs. 92 Crs) services for Tidewater M arine International etc Listed on NSE & BSE, Listed on NSE & BSE, Listed on NSE & BSE, Listed in AIM market, India India London India • Jubilant Bhartia Group : Valued around US $ 3Bn • Employs around 30,000 people across the globe with ~ 1400 in North America • Jubilant Bhartia Foundation, a not for profit organisation is a social arm of Jubilant Bhartia Group • The foundation is engaged in community development work focusing on primary education, basic healthcare, skill development through vocational training for youth & women • Aims at long term sustainable social intervention by empowering communities through 4P model (Public-Private-People-Partnership)

Jubilant Life Sciences – Overview • Providing Pharmaceutical & Life Sciences Revenue M ix by Geography products and services across the US $ 892 M n (Rs 4,278crs) Integrated pharmaceutical value chain Pharmaceutical • Ranked No. 6 amongst top 10 Global Pharma & outsourcing players as per UNCTAD* World Life Sciences Investment Report 2011 Domes tic Company • Reputed and High Quality relationships with 30% T op 20 Pharma companies, and 7 out of the top 10 Agrochemical companies globally • Low cost, multi location & vertically integrated ‘Partner of supplier Choice’ to Global Interna • Employs over 6300 people including 1400 in tional Life Sciences 70% North America and 1200 in R&D Companies • Part of Jubilant Bhartia Group, with founders shareholding at 49 %* * * United Nations Conference on Trade And Development report 2010 ** March 2013 3 3

Global Presence • • Present in India, North America, Europe and China Corporate Office and R&D Centres in Noida, India • • International sales in 98 countries Discovery Centre in Bangalore, India • • 7 manufacturing facilities in India and 3 in North America 50% assets in North America Dusseldorf, Germany M erelbeke , Belgium Jubilant Clinsys, Europe office Regulatory & Generic M arketing Kirkland, Quebec, Canada USFDA approved facility for contract manufacturing Non Sterile products and Noida, Uttar Pradesh Radiopharmaceuticals Shanghai, China Corporate Office & M arketing Office R&D Centres Ottawa, Canada DDDS office Spokane, Washington, USA Roorkee, Uttarakhand USFDA approved facility for contract UKM HRA, USFDA, PM DA, ANVISA manufacturing of Sterile injectable and approved facility for generics Allergy Therapy Products Gajraula, Uttar Pradesh Largest integrated pyridine & its derivatives facility in the world Horsham, Pennsylvania Jubilant Cadista - Sales & M arketing Head Office Lucknow M alvern, Pennsylvania, USA Samlaya, Gujarat DDDS Office Nutrition Products Salisbury, M aryland, USA USFDA approved facility for Bharuch, Gujarat generics (Tablets & Capsules) SEZ for Nutrition Products Bengaluru, Karnataka Pune and Pyridine derivatives State-of-art Discovery Centre Hyderabad Raleigh North Carolina, USA Clinical Research Centre and Ambarnath, M aharashtra Jubilant Life Sciences M arketing Office Pyridine derivatives Corporate Office Nanjangud, Karnataka M anufacturing Facilities USFDA, AFSSAPS & PM DA approval R&D Facilities Chennai APIs manufacturing facility Bedminster, New J ersey, USA Nira, M aharashtra International Subsidiaries Clinical Research Centre and Life Sciences Chemicals Indian Subsidiaries Jubilant Life Sciences -M arketing Office Branch Offices Not e: This illust rat ion is not exhaust ive. This illust rat ion is not t o scale 4 4

Key Financials REVENUE EBITDA 300 1000 892 723 770 639 175 186 200 $ Mn $ Mn 461 124 127 500 106 US US 100 0 0 FY08 FY09 FY10 FY11 FY12 FY08 FY09 FY10 FY11 FY12 For FY 2012: 1 USD = 47.95 INR | | For FY 2011: 1 USD=44.60 | | For previous years : 1 USD=46.53 Sustained growth momentum 5 5

Business Segments Jubilant Life Sciences Life Science Ingredients Pharmaceuticals M ix: 49% M ix: 51% Proprietary & Nutrition Ingredients APIs, Generics, Specialty M ix: 27% M ix: 30% Life Science Chemicals CM O & CRO M ix: 22% M ix: 21% Presence across the Value Chain in Pharmaceuticals and Life Science Ingredients 6 6 6

Business Segments Pharmaceuticals Segment – Profile & Growth drivers Profile Growth Drivers • • Strong product pipeline Focus Areas • APIs & Generics – CNS & CVS • 135 launches globally over 3 years • Radiopharmaceuticals – diagnostic products • 58 DM F and 50 ANDAs filed in US • CM O - sterile injectibles, non sterile products • Geographic expansion • Key growth markets – Regulated international markets • Europe, Japan, Emerging markets • Penetration in North America • Clients • Diversified client base • Increased capacity utilization • In APIs, Generics, CM O -sterile injectibles • Products • Diversified product base • Clinical Trials • CM O - extended service offerings in lab • USFDA approved manufacturing facilities in trials for commercial products • India, US • DDDS - Collaborative programs in discovery A, Canada & development Offering products and services in niche segments for top-end clients 7 7

Business Segments Life Science Ingredients Segment – Profile & Growth drivers Profile Growth Drivers • Offers Products for Industrial applications • Proprietary Products and Exclusive Synthesis - • Pharmaceuticals & Agrochemicals product launches including • Personal care, Food and Feed • S ymtet, Pyridine based ingredient for • Packaging, Textiles, Dyes, Inks insecticide • Vertically integrated in-house technology • Geographic expansion • Green feedstock for value added end products • Europe, US A, China & ROW • Proprietary Products and Exclusive S ynthesis – • Higher Capacity Utilization Pyridines & derivatives • Nutrition Ingredients – Niacinamide (vitamin B3) • Nutrition Ingredients - Vitamin B3 for Animal & Human Nutrition • Key growth markets – Europe, Emerging M arkets • Proprietary Products and Exclusive S ynthesis – S ymtet, Pyridines • GM P compliant M anufacturing facilities in India • Life Science Chemicals - Ethyl Acetate & Acetic Anhydride • Clients • Diversified client base • Ongoing R&D of new product applications for future growth Integrated player with low cost manufacturing for the Ingredients market 8 8